{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:39:50Z","timestamp":1791664790616,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008368","name":"Arthritis Society","doi-asserted-by":"publisher","award":["R186-A6654-B1757"],"award-info":[{"award-number":["R186-A6654-B1757"]}],"id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R287-2018-1094"],"award-info":[{"award-number":["R287-2018-1094"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:28:50Z","timestamp":1770697730000},"page":"1811-1824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8842-0186","authenticated-orcid":false,"given":"Maithri","family":"Aspari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0053","authenticated-orcid":false,"given":"Voon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esben","family":"N\u00e6ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene","family":"Hvid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-3887","authenticated-orcid":false,"given":"Kim","family":"Ravnskjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8322-180X","authenticated-orcid":false,"given":"Angela Y.Y.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3624-2410","authenticated-orcid":false,"given":"Shiwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2362-884X","authenticated-orcid":false,"given":"Xinyue","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-6057","authenticated-orcid":false,"given":"David","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-1587","authenticated-orcid":false,"given":"Bent","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-3307","authenticated-orcid":false,"given":"Stinne R.","family":"Greisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ard.2026.01.008_bib0001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.ard.2026.01.008_bib0002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0000000000000897","article-title":"Recent advances in elucidating the genetic basis of systemic sclerosis","volume":"34","author":"Villanueva-Mart\u00edn","year":"2022","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.01.008_bib0003","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41584-021-00683-2","article-title":"Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential","volume":"17","author":"Tsou","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.01.008_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"issue":"9","key":"10.1016\/j.ard.2026.01.008_bib0005","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/jcm11092299","article-title":"Systemic scleroderma-definition, clinical picture and laboratory diagnostics","volume":"11","author":"Kowalska-K\u0119pczy\u0144ska","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2026.01.008_bib0006","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"38","key":"10.1016\/j.ard.2026.01.008_bib0007","doi-asserted-by":"crossref","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.ard.2026.01.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115569","article-title":"The therapeutic potential of PD-1\/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components","volume":"167","author":"Zhang","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.ard.2026.01.008_bib0009","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2013.823517","article-title":"Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis","volume":"43","author":"Greisen","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"20","key":"10.1016\/j.ard.2026.01.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.ard.2026.01.008_bib0011","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/biomedicines9121929","article-title":"Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies","volume":"9","author":"Ohkuma","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ard.2026.01.008_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.827921","article-title":"Biological characteristics and clinical significance of soluble PD-1\/PD-l1 and exosomal PD-L1 in cancer","volume":"13","author":"Niu","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ard.2026.01.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2026.01.008_bib0014","article-title":"PD-1\/PD-L1 axis in organ fibrosis","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ard.2026.01.008_bib0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.ard.2026.01.008_bib0016","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/s41598-022-07044-3","article-title":"PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and \u03b2-catenin signaling pathways","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ard.2026.01.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125326","article-title":"PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis","volume":"4","author":"Geng","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ard.2026.01.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108504","article-title":"Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K\/Akt\/mTOR pathway","volume":"104","author":"Lu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ard.2026.01.008_bib0019","first-page":"17","article-title":"Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure\u2014a review with case series","volume":"26","author":"Akella","year":"2019","journal-title":"Respir Med Case Rep"},{"issue":"6","key":"10.1016\/j.ard.2026.01.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01105-2019","article-title":"The importance of interventional timing in the bleomycin model of pulmonary fibrosis","volume":"55","author":"Kolb","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ard.2026.01.008_bib0021","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"19","key":"10.1016\/j.ard.2026.01.008_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914438","article-title":"Enhanced innate and acquired immune responses in systemic sclerosis primary peripheral blood mononuclear cells (PBMCs)","volume":"24","author":"Szabo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ard.2026.01.008_bib0023","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3389\/fimmu.2018.01702","article-title":"Innate immunity in systemic sclerosis fibrosis: recent advances","volume":"9","author":"Laurent","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.01.008_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/aob-20-86","article-title":"A narrative review of PD-1 and autoimmune diseases","volume":"7","author":"Deng","year":"2021","journal-title":"Ann Blood"},{"issue":"1-2","key":"10.1016\/j.ard.2026.01.008_bib0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2006.10.006","article-title":"PD-1\/PD-L1, but not PD-1\/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis","volume":"182","author":"Carter","year":"2007","journal-title":"J Neuroimmunol"},{"issue":"10","key":"10.1016\/j.ard.2026.01.008_bib0026","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ard.2026.01.008_bib0027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000525887","article-title":"Scleroderma-like syndrome in the setting of pembrolizumab therapy for non-small cell lung cancer: diagnosis and dermatologic management","volume":"14","author":"Fattore","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.ard.2026.01.008_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"Ibis","year":"2023","journal-title":"Front Immunol"},{"issue":"460","key":"10.1016\/j.ard.2026.01.008_bib0029","doi-asserted-by":"crossref","first-page":"eaar8356","DOI":"10.1126\/scitranslmed.aar8356","article-title":"PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production","volume":"10","author":"Celada","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2026.01.008_bib0030","article-title":"Regulatory effect of PD1\/PD-ligand 1 (PD-L1) on Treg cells in patients with idiopathic pulmonary fibrosis","volume":"27","author":"Wang","year":"2021","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ard.2026.01.008_bib0031","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3389\/fimmu.2020.01602","article-title":"Systemic sclerosis perturbs the architecture of the immunome","volume":"11","author":"Paleja","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ard.2026.01.008_bib0032","first-page":"S98","article-title":"Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis","volume":"33","author":"Corallo","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.01.008_bib0033","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5114\/ceji.2021.109756","article-title":"Expression of macrophage migration inhibitory factor and its receptor CD74 in systemic sclerosis","volume":"46","author":"Ba\u00f1os-Hern\u00e1ndez","year":"2021","journal-title":"Cent Eur J Immunol"},{"issue":"11","key":"10.1016\/j.ard.2026.01.008_bib0034","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/annrheumdis-2021-220209","article-title":"Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis","volume":"80","author":"Gaydosik","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.008_bib0035","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ard.2026.01.008_bib0036","article-title":"What role does PDL1 play in EMT changes in tumors and fibrosis?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ard.2026.01.008_bib0037","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ard.2026.01.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108258","article-title":"PD-L1 reverse signaling in dermal dendritic cells promotes dendritic cell migration required for skin immunity","volume":"33","author":"Lucas","year":"2020","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.ard.2026.01.008_bib0039","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41590-023-01527-9","article-title":"Drivers of heterogeneity in synovial fibroblasts in rheumatoid arthritis","volume":"24","author":"Smith","year":"2023","journal-title":"Nat Immunol"},{"issue":"7760","key":"10.1016\/j.ard.2026.01.008_bib0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ard.2026.01.008_bib0041","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00281-015-0503-7","article-title":"Role of innate immune system in systemic sclerosis","volume":"37","author":"Fullard","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ard.2026.01.008_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102526","article-title":"Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis","volume":"113","author":"Worrell","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ard.2026.01.008_bib0043","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.matbio.2020.04.001","article-title":"T-cell regulation of fibroblasts and cardiac fibrosis","volume":"91-92","author":"Bradshaw","year":"2020","journal-title":"Matrix Biol"},{"issue":"4","key":"10.1016\/j.ard.2026.01.008_bib0044","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.01.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116282","article-title":"Comprehensive review of potential drugs with anti-pulmonary fibrosis properties","volume":"173","author":"Ma","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ard.2026.01.008_bib0046","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-024-04884-7","article-title":"Inhibitor of PD-1\/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis","volume":"22","author":"Tan","year":"2024","journal-title":"J Transl Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:06:40Z","timestamp":1788966400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0003496726000129"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.008","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}